CC
BIO icon

Clearline Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Clearline Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,535
Closed -$991K – 109
2025
Q3 		$991K Hold
3,535
– – 0.05% 94
2025
Q2 		$853K Hold
3,535
– – 0.03% 96
2025
Q1 		$861K Hold
3,535
– – 0.05% 94
2024
Q4 		$1.16M Sell
3,535
-12,244
-78% -$4.16M 0.15% 77
2024
Q3 		$5.28M Hold
15,779
– – 0.22% 66
2024
Q2 		$4.31M Hold
15,779
– – 0.12% 73
2024
Q1 		$5.46M Buy
+15,779
New +$5.19M 0.27% 54

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clearline Capital's BIO Position: Q4 2025 in Review

Clearline Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 3,535 shares — an estimated $991K sold.

Clearline Capital first reported a position in BIO in Q1 2024 and held it in 7 quarters. The position peaked at $5.46M in Q1 2024. 399 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

  • Clearline Capital reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
  • Clearline Capital sold 3,535 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $991K.
  • Clearline Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and held it in 7 quarters.
  • Clearline Capital's Bio-Rad Laboratories Class A position peaked at $5.46M in Q1 2024.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Clearline Capital's 13F filing for Q4 2025, filed 17 Feb 2026.